Drug Trial Radar · NCT01928394
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,163
Actual
Start
Oct 24, 2013
Primary completion
Feb 5, 2019
Study completion Nov 18, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.
Conditions
- Advanced or Metastatic Solid Tumors
Interventions
NivolumabBiological
IpilimumabBiological
CobimetinibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate ( ORR )Time frame: 60 months
Locations
38 sites in 8 countries. Site status is shown where the registry gives one.
Local Institution - 0047
Muscle Shoals, Alabama
Local Institution - 0044
Aurora, Colorado
Local Institution - 0015
New Haven, Connecticut
Local Institution - 0046
Gainesville, Florida
Local Institution - 0021
Tampa, Florida
Local Institution - 0001
Atlanta, Georgia
Local Institution - 0004
Baltimore, Maryland
Local Institution - 0005
Boston, Massachusetts
Local Institution - 0043
Boston, Massachusetts
Local Institution - 0049
Omaha, Nebraska
Local Institution - 0045
Mineola, New York
Local Institution - 0006
New York, New York
Local Institution - 0003
Charlotte, North Carolina
Local Institution - 0008
Durham, North Carolina
Local Institution - 0007
Portland, Oregon
Local Institution - 0011
Franklin, Tennessee
Local Institution - 0002
Nashville, Tennessee
Local Institution - 0009
Houston, Texas
Local Institution - 0042
Seattle, Washington
Local Institution - 0038
Toronto, Ontario, Canada
Local Institution - 0039
Copenhagen, Denmark
Local Institution - 0036
Tampere, Finland
Local Institution - 0014
Helsinki, Uusimaa, Finland
Local Institution - 0048
Bonn, Germany
Local Institution - 0026
Frankfurt, Germany
Local Institution - 0016
Heidelberg, Germany
Local Institution - 0050
Kassel, Germany
Local Institution - 0024
Bologna, Italy
Local Institution - 0019
Milan, Italy
Local Institution - 0020
Naples, Italy
Local Institution - 0032
Padova, Italy
Local Institution - 0037
Barcelona, Spain
Local Institution - 0023
Madrid, Spain
Local Institution - 0017
Madrid, Spain
Local Institution - 0010
Madrid, Spain
Local Institution - 0018
London, Greater London, United Kingdom
Local Institution - 0012
Glasgow, Lanarkshire, United Kingdom
Local Institution - 0013
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.